Investor Alert: Robbins LLP Informs Investors of the Savara Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period from March 7, 2024, to May 23, 2025 [1][2]. Allegations - The complaint states that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [2]. - The company misrepresented the timeline for completing the BLA submission, leading to increased chances of needing additional capital due to delays in regulatory approval [2]. Stock Price Impact - Following the announcement of a refusal to file (RTF) letter from the FDA on May 27, 2025, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share [3].